Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

After catching up with Pfizer’s Chairman and CEO, CFO, Chief Scientific Officer and Chief Strategy and Innovation Officer at the firm’s healthcare conference, JPMorgan analyst ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...